Phosplatin Therapeutics Completes First Fully-Robotic cGMP Drug Product Batch of PT-112 with Baxter BioPharma Solutions’ Halle/Westfalen Germany Facility

NEW YORK, NY November 07, 2019 – Phosplatin Therapeutics LLC, a clinical stage pharmaceutical company focused on oncology therapeutics, today released its first successful cGMP batch using a fully-automated drug product manufacturing process at Baxter BioPharma Solutions, Halle/Westfalen, Germany, expanding its manufacturing capabilities for use of PT-112 during remaining clinical development. This step represents both a scale-up measure and a significant advancement of the process and technological capabilities within the pre-commercial chemistry manufacturing and controls (CMC) efforts by the company. Baxter BioPharma Solutions is a highly specialized provider of manufacturing services for cytotoxic and highly potent products for use in oncology therapeutics.

"Our newly launched collaboration with Baxter BioPharma Solutions is a reflection of our expansion and growth as a company, and our preparations for commercial launch of PT-112,” said Matthew Price, Executive VP and Chief Operating Officer of Phosplatin Therapeutics. “Baxter brings expertise and state-of-the-art technology, and we look forward to an ongoing collaboration.”